anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Besides the high prevalence of HIV and HCV infections, people who inject drugs (PWID) have a cumulative risk of acquiring skin and soft tissue infections (SSTI) from, among other things, social precariousness, homelessness/unstable housing, and unhygienic injecting practices. We propose to evaluate whether a two-component educational hand hygiene intervention which combines training in hand-washing with the supply of a single-use alcohol-based hand rub, called MONO-RUB, is effective in reducing injection-related abscesses in the PWID population. Specifically, we shall implement a nationwide, two-arm, multi-centre, cluster randomised controlled trial to evaluate the effectiveness and cost-effectiveness of this intervention in PWID.
METHODS: HAWA is a community-based participatory research study to be conducted in 22 harm reduction centres (HR) in France (not yet recruiting); the latter will be randomised into two clusters: centres providing standard HR services and the intervention (i.e., intervention group) and those providing standard HR services only (i.e., control group). After randomization, each cluster will include 220 PWID, with an inclusion period of 12 months and an individual follow-up period of 6 months. For each participant, we will collect data at M0, M3 and M6 from photos of injection sites on the participant's body, a face-to-face injection-related SSTI questionnaire, and a CATI questionnaire. The primary outcome is the reduction in abscess prevalence between M0 and M6, which will be compared between the control and intervention arms, and measured from observed (photographs) and self-declared (SSTI questionnaire) data. We will also assess the cost-effectiveness of the intervention.
DISCUSSION: The HAWA trial will be the first cluster randomized controlled trial to improve hand hygiene among PWID with a view to reducing SSTI. If effective and cost-effective, the intervention combined with the distribution of MONO-RUBs (or a similar cleaning product) may prove to be an important HR tool, helping to reduce the enormous burden of infection-related deaths and diseases in PWID.
TRIAL REGISTRATION: NCT06131788, received on 2 January 2024.
Treatment options for sarcopenia are currently limited, and primarily rely on two main therapeutic approaches: resistance-based physical activity and dietary interventions. However, details about specific nutrients in the diet or supplementation are unclear. We aim to investigate the relationship between nutrient intake and lean mass, function, and strength. Data were derived from the Gothenburg H70 birth cohort study in Sweden, including 719,70-year-olds born in 1944 (54.1% females). For independent variables, the diet history method (face-to-face interviews) was used to estimate habitual food intake during the preceding three months. Dependent variables were gait speed (muscle performance), hand grip strength (muscle strength), and the appendicular lean soft tissue index (ALSTI). Linear regression analyses were performed to analyze the relationship between the dependent variables and each of the covariates. Several nutrients were positively associated with ALSTI, such as polyunsaturated fatty acids (DHA, EPA), selenium, zinc, riboflavin, niacin equivalent, vitamin B12, vitamin D, iron, and protein. After correction for multiple comparisons, there were no remaining correlations with handgrip and gait speed. Findings of positive correlations for some nutrients with lean mass suggest a role for these nutrients in maintaining muscle volume. These results can be used to inform clinical trials to expand the preventive strategies and treatment options for individuals at risk of muscle loss and sarcopenia.
FIELD: medicine and pharmacy. SUBSTANCE: described are new bioaromatic compounds of general formula I, wherein R 1 , R 2 , R 3 , X and Ar are as defined in claim 1. They are active in differentiation and proliferation of cells. Also described is pharmaceutical composition intended for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological diseases and cosmetic composition for hygiene of body and care of hair. EFFECT: improved properties of the pharmaceutical and cosmetic composition. 17 cl, 22 ex, 4 dwg
This is a prospective, randomised, control trial of 40 participants. Twenty patients in each arm. Twenty patients undergo standard pterygium excision with the conjunctival autograft sutured. Twenty patients undergo pterygium surgery with Tisseel glue replacing sutures as a method of attaching the conjunctival autograft. Participants will be reviewed, selected, and consented on a pre-assessment day. Surgery will be performed 10 at a time on an all day surgery operating list. Randomisation of the surgery type will be done at the time of surgery after the pterygium has been excised and the autograft taken. One surgeon (R. Hall) will perform all of the procedures. Follow-up will occur at week 1, 2, 4, 26, 52. A questionnaire answered by participants will indicate their pain, foreign body sensation, tearing, and discomfort. There will be observation of any complications such as graft failure and recurrence rate. Photographs will be taken pre-op and post-op.
This will be a single-arm study where all study participants will receive transcutaneous vagus nerve stimulation (tVNS) at the cymba concha of the left ear for 60 minutes. The tVNS parameters will be a below-discomfort-threshold intensity with 25 Hz and a pulse width of 250 uS.
The invention discloses bacillus subtillis and a method for preparing raw powder of each gram of bacillus subtillis with 1 trillion live germs. The bacillus subtillis is CCTCC: No. M209317. The method comprises the following steps of: A, screening of a Bs strain: collecting a sample from soil and water, adding sterile water into the sample and standing the sample; B, confirmation of the Bs strain: together measuring 1,244 effective basic groups in 16SrDNA of the stain; C, screening of Bs culture medium: determining an optimal factor from numerous carbon sources, nitrogen sources and trace element factors by adopting a response surface experiment of Box-Behken design and using the germ number as a screening index; D, improving the quantity of fermentation organisms, and performing batch fermentation by using the culture medium screened by a response surface method; E, extracting and reclaiming the germs; and F, detecting the number of the live germs, namely accurately detecting the number of the effective live germs in the product. The method has the advantages of good repeatability, low cost, capability of simultaneously detecting 7 to 8 samples and simple operation. The produced bacillus subtillis has the advantages of clean and safe raw medicament, high reclamation rate, stable germ number of the product, capability of reaching 1 trillion live germs in each gram and the like.
Standardized Grass Pollen Extracts include: Orchard (Dactylis glomerata), Perennial Rye (Lolium perenne), Timothy (Phleum pratense), Redtop (Agrostis alba), Kentucky (June) Bluegrass (Poa pratensis), Bermuda (Cynodon dactylon), Meadow Fescue (Festuca elatior), Sweet Vernal (Anthoxanthum odoratum). The standardized grass pollen extract is prepared by extracting raw pollen material at a ratio of either 1:5 w/v, 1:6.66 w/v or 1:10 w/v in Cocas fluid containing 0.5% NaCl, 0.275% NaHCO3, WFI and 0.4% phenol as preservative. Following extraction, a calculated amount of glycerin is added to make a 50%(v/v) glycerinated solution. Standardized Grass Pollen extracts have potency designations of 10,000 BAU/mL and 100,000 BAU/mL except Bermuda Grass (10,000 BAU/mL only). Extracts with a potency of 10,000 BAU/mL are diluted from the 100,000 BAU/mL lots with Glycerol Saline 50%(v/v). The Glycerol Saline 50%(v/v) solution consists of Glycerin and Salts and Buffered Diluent whose ingredients are 0.5% NaCl, 0.08% Na2HPO4, 0.036% KH2PO4, WFI and 0.4% phenol as a preservative. All extracts are aseptically filled in sterile containers. Standardized pollen extracts are intended for administration by prick-puncture or intradermal routes when used for diagnostic purposes and administered subcutaneously when used for immunotherapy injection.

Standardized grass pollen extracts labeled in BAU/mL are not interchangeable with grass pollen extracts labeled in AU/mL or with non-standardized grass pollen extracts. The Bioequivalent Allergy Unit (BAU), the potency unit used for all Standardized Pollen Extracts, replaces the previous unitage for these products. Bioequivalent Allergy Units were assigned to the FDA, Center for Biologics Evaluation and Research (CBER) reference extracts, based on quantitative intradermal skin test results. BAU's are intended to assure that the labeled unitage of different allergenic extracts will correspond to the expected clinical response in sensitive patients. References labeled 10,000 BAU/mL can be diluted one half million fold to produce an intradermal sum of erythema diameter response of 50mm in highly puncture reactive subjects. 100,000 BAU/mL can be diluted 1:5 million fold to yield the same intradermal response.(2) The assignment of BAU/mL to standardized grass pollen extracts, is accomplished by an ELISA assay comparing the extract to the CBER reference.

Previously, the potency / concentration of grass mixtures was designated based on the manufacturing strength, e.g. 1:10 w/v or 1:20 w/v, or in PNU's/mL. For grass mixtures containing standardized extracts, the potency will reflect the contribution of each individual component in the mixture, i.e., the actual potency of each component will be listed on a per mL basis. In addition, because the individual components may be cross-reactive, an additional caution statement, "due to cross reactivity, total potency may be 100,000 BAU/mL," will be added to the label.
<P>PROBLEM TO BE SOLVED: To provide compounds, compositions and methods for regulating the activity of a nuclear receptor.  <P>SOLUTION: The compounds used in the compositions and methods for regulating the nuclear receptors, especially liver X receptor (LXRα and LXRβ), FXR, PPAR and/or orphan nuclear receptor are provided. In a certain embodiment these compounds are N-substituted pyridone compounds. In an embodiment, a compound provided in the specification is an agonist of LXR. In another embodiment, a compound provided in the specification is an antagonist of LXR. An agonist low in effectiveness is an antagonist in a certain embodiment.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Pregnant women feel severe pain during normal birth and in the postpartum period. Preventing pain during and after birth is very important for both the mother and the baby. Rapid recovery in the postoperative period in pregnant women is very important for both mother and baby. To evaluate this recovery, the quality of recovery-10 scores developed by Shalev et al. are used in pregnant women. Our study will be the first in the literature to use sacral erectör spinae plane block in normal birth. Our primary aim in this study is to evaluate the effects of sacral erectör spinae plane block on the quality of recovery and recovery at the 24th hour in pregnant women who will undergo vaginal birth with epidural analgesia, using the Quality of recovery-10T score. the numeric rating scale at the 0-15th minute-30th minute-45th minute-1-2-4-8-12-24th hour after the S-ESPB application, and to evaluate the patient satisfaction at the 24th hour with a Likert scale. , the total amount of rescue analgesic ( bupivacaine ) consumed since the application of sacral erectör spinae plane block, the number of pregnant women given oxytocin, the time of the first breastfeeding, complications in the mother (fever, nausea, vomiting, motor block, hip pain), the need for antiemetics, the baby's 1st and 5th minutes. Apgar score at the 1st-2nd-3rd week of birth. is to evaluate the duration of the phases .
Peginterferon alfa-2b will be administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
<P>PROBLEM TO BE SOLVED: To provide a new non-human animal model such as mice for modeling neurodegenerative diseases including amyloidopathies, especially AD (Alzheimer's disease).  <P>SOLUTION: The new animal model for amyloidopathies, especially Alzheimer's disease overexpressing human BACE and human APP London. This new animal model exhibits several aspects of amyloidopathy and has utility in developing specific and general therapies for amyloidopathies. Moreover, this animal model can be used for screening methods to identify new anti-amyloidogenic compounds and for testing their therapeutic effect. A method for producing said double transgenic animals, cells and cell lines derived from these animals, and a kit comprising these cells for screening compounds useful for amyloidopathies, are also provided, respectively. Moreover, a method for the evaluation of the in vivo effects of beta-secretase activity on A-beta peptide generation, amyloidosis, neurodegeneration and AD pathology in these animals is also provided.  <P>COPYRIGHT: (C)2004,JPO
Participants in the intervention group will receive one 20-30 minutes "5A" smoking cessation health consultation after enrollment; They will be given regular phone-based smoking cessation intervention once a week in the first month and once a month thereafter (15 times in total). Participants will be followed at 2, 6, 12 months, and cotinine urine test kits will be mailed to those who have self-reported smoking cessation at follow-up, which is used to confirm whether they have quitted smoking or not. (smoking cessation is defined as urine cotinine levels below 200 ng/mL).
FIELD: medicine, immunology, gastroenterology. SUBSTANCE: method to induce protective immune response in a host to helicobacter infection deals with injection of immunogenously efficient amount of helicobacter antigen for a host for further usage in people while obtaining the mentioned protective immune response. Mentioned helicobacter antigen is that of helicobacter pilori and phelis. Vaccine to treat helicobacter infection includes immunogenously efficient amount of helicobacter antigen in association with pharmaceutically acceptable carrier or solvent. Method to obtain passive protective response against helicobacter infection in mammalian host also deals with injection of immunologically efficient amount of helicobacter - specific antibody which represents IgA antibody. EFFECT: higher efficiency to create vaccines which contain some amount of helicobacter antigen that is efficient to induce protective immune response. 3 cl, 14 cl, 3 dwg , 2 tbl
OBJECTIVE: We analyzed quantitative computed tomography (CT) and chemical shift-encoded magnetic resonance imaging (MRI) data from a Chinese cohort to investigate the effects of BMI and aging on different adipose tissue (AT) depots.
METHODS: In 400 healthy, community-dwelling individuals aged 22 to 83 years, we used MRI to quantify proton density fat fraction (PDFF) of the lumbar spine (L2-L4) bone marrow AT (BMAT), the psoas major and erector spinae (ES) muscles, and the liver. Abdominal total AT, visceral AT (VAT), and subcutaneous AT (SAT) areas were measured at the L2-L3 level using quantitative CT. Partial correlation analysis was used to evaluate the relationship of each AT variable with age and BMI. Multiple linear regression analysis was performed in which each AT variable was evaluated in turn as a function of age and the other five independent AT measurements.
RESULTS: Of the 168 men, 29% had normal BMI (<24.0 kg/m2), 47% had overweight (24.0-27.9 kg/m2), and 24% had obesity (≥ 28.0 kg/m2). In the 232 women, the percentages were 46%, 32%, and 22%, respectively. Strong or very strong correlations with BMI were found for total AT, VAT, and SAT in both sexes. BMAT and ES PDFF was strongly correlated with age in women and moderately correlated in men. In both sexes, BMAT PDFF correlated only with age and not with any of the other AT depots. Psoas PDFF correlated only with ES PDFF and not with age or the other AT depots. Liver PDFF correlated with BMI and VAT and weakly with SAT in men. VAT and SAT correlated with age and each other in both sexes.
CONCLUSIONS: Age and BMI are both associated with adiposity, but their effects differ depending on the type of AT.
A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). The experimental diet will meet UK dietary guidelines for fiber, salt, sugar, saturated fat, fruit and vegetable intake. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant. The diet will be consumed across 3 consecutive night shifts.
Participants in this group are children diagnosed with gastroparesis per gastric emptying scintigraphy. Participants will be receiving a gastric emptying breath test three times over the course of 6 months and an ultrasound of the stomach once.
Depressive disorders are among the most common psychiatric disorders in childhood and adolescence and yet often are unnoticed and not treated for a long time. Depressive disorders often begin in adolescence and young adulthood. School stress, caused by bullying experiences at school or high performance expectations from parents and teachers, has been identified as an important factor in the development of depressive disorders in students. School, as a central area of life for children and young people, is an important place for promoting pupils' mental health. The rising prevalence of depressive disorders among adolescence in recent years and the delayed start of interventions show a clear need for action in the everyday lives of adolescents. The Department of Child and Adolescent Psychiatry of the Hospital of the LMU Munich and the Beisheim Foundation launched the innovative digital information portal "Ich bin alles @Schule" (i am everything @school; www.schule.ich-bin-alles.de) in November 2023. "ich bin alles @Schule" is a German information platform that was developed for educational professionals and aims to provide low-threshold information about depression and mental health in the school context.

Due to the high relevance of comprehensively evaluating web-based information services on mental health and mental illness, the aim of this study is to use established methods to learn more about the visitors of "ich bin alles @Schule" and their user experience.

The aim of the study is a scientific evaluation of the naturalistic user experience of "Ich bin alles @Schule" users. For this purpose, an online questionnaire and the website analysis tool "Matomo" is applied. The study is intended to provide clues as to whether the "ich bin alles @Schule" information platform is a useful and trustworthy source of information for the target group. The information obtained is of central importance for potential adaptations and optimizations of the website. Another aim of this study is to determine whether we can actually reach the desired target group with our website. The results of the data collection also provide an important basis for future approaches aimed at school professionals about mental health issues and mental illness in a way that is appropriate for the target group.
No dose adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been studied. The use of VIVLODEX in subjects with severe renal impairment is not recommended. In a previous study, the free Cmax plasma concentrations following a single dose of meloxicam were higher in patients with renal failure on chronic hemodialysis (1% free fraction) in comparison to healthy volunteers (0.3% free fraction). Therefore, the maximum VIVLODEX dosage in this population is 5 mg per day. Hemodialysis did not lower the total drug concentration in plasma; therefore, additional doses are not necessary after hemodialysis. Meloxicam is not dialyzable [see Warnings and Precautions (5.6), Clinical Pharmacology (12.3)].
PROBLEM TO BE SOLVED: To obtain a blood vessel occlusive agent giving minor invasiveness to a patient and utilizable for an ultrasonic device for occluding a blood vessel, by encapsulating a blood vessel occlusive substance-forming agent in microcapsules. SOLUTION: This blood vessel occlusive agent 20 is produced by encapsulating a blood vessel occlusive substance-forming agent in microcapsules 22. The blood vessel occlusive agent 20 preferably comprises a blood coagulation accelerator 24 encapsulated in microcapsules 22. The microcapsule 22 comprises a substance which is successively decomposed in an organism, and a hydrolyzable polymer (for example, a polymer such as polylactide or polyglycolide) is preferably exemplified. Thrombin, thromboplastin or the like is preferably used as the blood coagulation accelerator 24. A highly water-absorbing polymer and an adhesive, such as cyanoacrylate, can be preferably encapsulated in the microcapsule 22 as a substituent for the blood coagulation accelerator 24.  A gas (for example, air and nitrogen gas) is preferably additionally encapsulated together with the blood coagulation accelerator 24 or the like.
The invention relates to a traditional Chinese medical composition for treating hypertension. The medicine comprises the components in parts by weight as follows: 100-150 parts of lumbricus, 100-150 parts of Scorpio, 100-150 parts of leech, 100-150 parts of pseudo-ginseng, 100-150 parts of mother chrysanthemum, 100-150 parts of flowers carthami, 100-150 parts of Rhizoma Atractylodis Macrocephalae and 100-150 parts of radix paeoniae alba, wherein lumbricus, Scorpio, leech, mother chrysanthemum and flowers carthami are main medicines and are mainly used to promote blood circulation to remove blood stasis, reduce blood pressure and improve microcirculation; and Rhizoma Atractylodis Macrocephalae and radix paeoniae alba are auxiliary medicines and are mainly used to tonify qi and yin and prevent the medicines for promoting blood circulation to remove blood stasis in the main medicines from consuming qi and damaging moist. Based on the principle of diagnosis and treatment in traditional Chinese medicines, the composition addresses both the symptoms and root cause, regulates inside and outside and treats slow and emergent diseases. Natural plant medicines which promote blood circulation to remove blood stasis, clear and activate the channels and collaterals and tonify qi and yin are screened, and the composition is prepared by a certain weight ratio according to the theory of traditional Chinese medicine. Used for treating hypertension, the traditional Chinese medical composition provided by the invention is remarkable in curative effect, free from toxic and side effects, low in cost, simple to prepare, and convenient for patients to use. Clinical verification shows that the effective rate of the composition provided by the invention for treating hypertension is 99%.
Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.